Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine
Status:
Completed
Trial end date:
2009-04-01
Target enrollment:
Participant gender:
Summary
In this study, a melanoma vaccine (5 melanoma peptides) is given with either Montanide or
dendritic cells as adjuvants. This randomized trial will establish the safety of both
vaccines and compare the 2 vaccine adjuvants in their efficacy to induce immune responses.